Systemic inflammation within malignant glioma is a topic of ongoing significance. In this commentary, we highlight recent findings from Gandhi et al and discuss alternative approaches. We present a counter argument with findings that IL-6 markers are controversial. We highlight the potential benefit of looking at microRNAs and other biomarkers. Finally, we present ideas for future application involving differentiation between radiation necrosis and recurrence. The commentary is intended to serve as a catalyst for further scientific discovery.
Keywords: Interleukin-6; Malignant glioma; Neutrophil-lymphocyte ratio; Systemic inflammation.
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.